{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-054341","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-08-06T20:16:48+00:00","discovered_at":"2026-08-06T20:18:00.324379+00:00","generated_at":"2026-08-06T20:19:18.087180+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vistagen Phase 2 fasedienol study: safety met, numerical separation on primary; nominally significant in severe SAD","bullets":["Safety objective met: repeat dose fasedienol safety comparable to single dose, no new findings.","Primary endpoint (SUDS change) numerical separation from placebo but not statistically significant (pooled p=0.2).","In very severe SAD (LSAS≥95), pooled fasedienol showed nominally significant improvement (p=0.04, Cohen's d=0.78).","CGI-I and PGI-C responder rates directionally higher for fasedienol; repeat dose arm >2x placebo.","Exploratory anticipatory anxiety endpoint: repeat dose (p=0.01) and pooled (p=0.03) nominal significance."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-054341","json":"https://secwatch.observer/filing/0001628280-26-054341.json","markdown":"https://secwatch.observer/filing/0001628280-26-054341.md","text":"https://secwatch.observer/filing/0001628280-26-054341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026054341/0001628280-26-054341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026054341/vtgn-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:19:18.087180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}